High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C

Background: High prices of direct acting antivirals (DAAs) for hepatitis C virus (HCV) can lead to restrictions on access to treatment in high- and middle-income countries. An increasing number of people in these countries are treating their HCV infection with generic drugs produced in India, China,...

Full description

Bibliographic Details
Main Authors: Andrew Hill, Giten Khwairakpam, James Wang, Sergey Golovin, Julia Dragunova, Rachel Smith, Vicky Houghton-Price, Roxanna Korologou-Linden, Sanjay Nath, Anna Savage, Greg Jefferys
Format: Article
Language:English
Published: Elsevier 2017-10-01
Series:Journal of Virus Eradication
Subjects:
hepatitis C, direct acting antivirals, sofosbuvir, ledipasvir, daclatasvir
Online Access:http://www.sciencedirect.com/science/article/pii/S2055664020303241

Similar Items

Similar Items